Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.55 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 5/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404354 | 1.00 | ABCG2 (0.55) | ABCG2ESR1PGRKIF11HTR2A | |
| SCHEMBL764905 | 0.88 | KIF11 (0.53) | ABCG2KIF11HTR2AABCB1DHODH | |
| SCHEMBL13696261 | 0.86 | KIF11 (0.62) | ABCG2ESR1PGRKIF11HTR2A | |
| SCHEMBL764589 | 0.85 | TP53 (0.56) | ABCG2KIF11HTR2BLMNASMN1; SMN2 | |
| SCHEMBL764129 | 0.84 | ABCG2 (0.63) | ABCG2KIF11LMNASMN1; SMN2NPSR1 | |
| SCHEMBL3576710 | 0.80 | KIF11 (0.75) | ABCG2KIF11LMNAPOLB | |
| SCHEMBL764693 | 0.80 | ABCG2 (0.58) | ABCG2KIF11LMNASMN1; SMN2NPSR1 | |
| SCHEMBL9962250 | 0.77 | TP53 (0.59) | ABCG2KIF11LMNASMN1; SMN2ABCB1 | |
| SCHEMBL3344851 | 0.77 | TP53 (0.59) | ABCG2KIF11LMNASMN1; SMN2ABCB1 | |
| SCHEMBL3344853 | 0.77 | TP53 (0.59) | ABCG2KIF11LMNASMN1; SMN2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2010-06-24 | — | — | US | claimed |
| EP-2139476-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC Therapeutics, Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008127714-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| WO-2008127715-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-1737461-B1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| WO-2008127714-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | RNMT, VEGFA, VHL | ABCG2 4594/4885ESR1 4252/4885PGR 2740/4885 |
| US-20080064683-A1 | Inhibition of VEGF Translation | EIF4E, EIF4EBP1, VEGFA | ABCG2 3060/4885ESR1 4283/4885PGR 2846/4885 |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | ABCG2 3195/4885ESR1 2111/4885PGR 910/4885 |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | ABCG2 3386/4885ESR1 2536/4885PGR 997/4885 |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | EIF2AK2, POLRMT, POLM | ABCG2 4448/4885ESR1 4820/4885PGR 4281/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | ABCG2 1872/4885ESR1 3414/4885PGR 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.